Medikinet

Methylphenidate, the active ingredient in Medikinet, is a central nervous system stimulant presented as oral tablets for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Medikinet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medikinet is a psychostimulant that acts on the central nervous system to improve attention and wakefulness. - Attention deficit hyperactivity disorder (children): improves focus and reduces hyperactivity. - Attention deficit hyperactivity disorder (adults): enhances attention and executive function. - Narcolepsy: decreases daytime sleepiness and improves wakefulness.

Common side effects are generally mild and transient, while serious or rare reactions require immediate medical attention.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced desire for food, potentially affecting weight. - Headache: mild to moderate head pain. - Stomach pain: abdominal discomfort or cramps.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or other heart‑related issues. - Psychosis or severe mood changes: hallucinations, delusions, or marked agitation. - Allergic reactions: rash, swelling, or anaphylaxis requiring urgent care.

Before prescribing Medikinet, clinicians should consider several safety factors. - Assess cardiovascular status: evaluate blood pressure and heart rate prior to initiation. - Monitor growth in children: regularly track height and weight. - Screen for psychiatric history: watch for emergence of psychosis or mood disorders. - Avoid use in patients with known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Methylphenidate may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Antihypertensives: potential reduction in blood‑pressure‑lowering effect. - Anticonvulsants: possible alteration of methylphenidate plasma levels. - CYP2D6 inhibitors: may raise methylphenidate concentrations, requiring dose adjustment.